What are the diagnostic criteria and treatment options for a patient from Mediterranean, Middle Eastern, or South Asian descent with a family history of thalassemia, presenting with anemia, fatigue, and jaundice?

Diagnosis of Thalassemia

Initial Screening Approach

All patients from Mediterranean, Middle Eastern, or South Asian descent presenting with anemia, fatigue, and jaundice should undergo complete blood count (CBC) with specific attention to mean corpuscular volume (MCV), as MCV <80 fL is the primary screening indicator for thalassemia carrier status. 1, 2

Key Laboratory Parameters for Initial Screening

• MCV <80 fL is the critical threshold that triggers further thalassemia workup, particularly in at-risk ethnic populations 1, 2
• Red blood cell (RBC) count is typically normal or elevated in thalassemia trait, which distinguishes it from iron deficiency anemia where RBC count is usually low 1
• Red cell distribution width (RDW) ≤14.0% suggests thalassemia trait, while RDW >14.0% suggests iron deficiency anemia 1
• Serum ferritin must be measured to exclude concurrent iron deficiency, as iron deficiency can mask thalassemia trait characteristics and falsely lower HbA2 levels 1

Critical Pitfall to Avoid

If iron deficiency is present (ferritin below reference range), you must provide iron replacement therapy before performing hemoglobin analysis, as iron deficiency falsely lowers HbA2 levels and masks the diagnosis of beta-thalassemia trait. 1 This is one of the most common diagnostic errors in thalassemia workup.

Confirmatory Diagnostic Testing

Hemoglobin Analysis

• After excluding or correcting iron deficiency, proceed with hemoglobin electrophoresis or high-performance liquid chromatography (HPLC) to measure HbA2 and HbF levels 3, 4
• Elevated HbA2 (>3.5%) confirms beta-thalassemia trait 4
• Hemoglobin H (HbH) detection indicates alpha thalassemia (three-gene deletion) 2, 5

DNA-Based Molecular Testing

• DNA testing for deletions or point mutations is the definitive diagnostic test to identify the specific genetic defect and is essential for genetic counseling 2, 4
• More than 200 disease-causing mutations have been identified in beta-thalassemia, with the majority being single nucleotide substitutions, deletions, or insertions 4
• Molecular testing is required for confirmation of results and for prenatal and preimplantation genetic diagnosis 3

Clinical Severity Classification

Beta-Thalassemia Spectrum

• Beta-thalassemia carrier state (trait): Clinically asymptomatic with specific hematological features (microcytosis, elevated HbA2) 4
• Thalassemia intermedia: Clinically heterogeneous, ranging from asymptomatic to requiring occasional transfusions 6, 4
• Thalassemia major: Severe transfusion-dependent anemia requiring regular lifelong transfusions and iron chelation therapy 6, 4

Alpha-Thalassemia Spectrum

• Silent carrier (one-gene deletion): Asymptomatic with normal laboratory values 2
• Alpha-thalassemia trait (two-gene deletion): Mild microcytic anemia 2
• Hemoglobin H disease (three-gene deletion): Moderate hemolytic anemia requiring monitoring every 3-6 months 2, 5
• Hemoglobin Bart's hydrops fetalis (four-gene deletion): Typically fatal condition causing non-immune hydrops fetalis 2, 5

Family Screening and Genetic Counseling

Partner Screening Protocol

When a patient is identified as a thalassemia carrier, partner screening is mandatory to determine if the couple is at risk for having an affected child. 1 This is non-negotiable for proper genetic counseling.

• Partner screening should include CBC with MCV measurement, and if MCV <80 fL, proceed with hemoglobin analysis and DNA testing 1, 5
• If both partners are carriers, they face a 25% risk with each pregnancy of having an affected child 1, 5

Genetic Counseling Requirements

• Provide clear, nondirective counseling covering: the name and characteristics of the carrier state, the disease the baby could be at risk for, characteristics of the disease, risks to the child, and options including no further action or prenatal diagnosis 1
• Emphasize ethnicity-specific risks: alpha thalassemia is most common in Southeast Asian populations, while beta thalassemia predominates in Mediterranean, Middle Eastern, and South Asian populations 1, 2

Prenatal Diagnosis for At-Risk Couples

When both partners are carriers, offer:

• Chorionic villus sampling (CVS) at 10-13 weeks gestation for DNA-based testing to detect common deletions or point mutations 1, 5
• Amniocentesis at 15-20 weeks gestation as an alternative to CVS for DNA analysis 1, 5
• Ultrasound surveillance in the late second and early third trimester to detect hydrops fetalis in severe alpha thalassemia 1, 5

Treatment Considerations Based on Diagnosis

Thalassemia Major Management

• Regular blood transfusions maintaining pre-transfusion hemoglobin of 9-10 g/dL with post-transfusion hemoglobin of 13-14 g/dL 6
• Iron chelation therapy is mandatory to remove excess iron from transfusions 6, 4
• Hematopoietic stem cell transplantation is the only curative option, with current survival rates >90% and disease-free survival around 80% 7

Thalassemia Intermedia Management

• May not require regular transfusions initially but often need them as they age to prevent cardiovascular and other complications 6
• Iron chelation becomes necessary when transfusions are initiated 6

Alpha Thalassemia (HbH Disease) Management

• Monitor with CBC every 3-6 months to assess for worsening hemolytic anemia and determine transfusion needs 2, 5
• Avoid inappropriate iron supplementation, which can worsen hemosiderosis 5

Common Diagnostic Pitfalls

• Failure to consider ethnicity in the diagnostic approach can lead to missed diagnoses 2
• Testing for thalassemia without first correcting iron deficiency leads to false-negative results for beta-thalassemia trait 1
• Failure to screen the partner of a known carrier results in missed diagnosis of at-risk pregnancies 5
• Misinterpreting macrocytosis during treatment, as it can occur with both folate deficiency and as a normal response to therapy 8